{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T19:40:35Z","timestamp":1792525235107,"version":"4.5.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T00:00:00Z","timestamp":1784764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T00:00:00Z","timestamp":1792454400000},"content-version":"vor","delay-in-days":89,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100007270","name":"University of Michigan","doi-asserted-by":"publisher","award":["Michigan Medicine (Support for Outstanding Academic Research)"],"award-info":[{"award-number":["Michigan Medicine (Support for Outstanding Academic Research)"]}],"id":[{"id":"10.13039\/100007270","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["EJNMMI radiopharm. chem."],"DOI":"10.1186\/s41181-026-00482-8","type":"journal-article","created":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T16:14:18Z","timestamp":1784823258000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Assessment of PET drug adverse events in the U.S. since the implementation of 21 CFR part 212"],"prefix":"10.1186","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2894-0136","authenticated-orcid":false,"given":"Marianna","family":"Dakanali","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry F.","family":"VanBrocklin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven S.","family":"Zigler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6505-0450","authenticated-orcid":false,"given":"Peter J. H.","family":"Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,23]]},"reference":[{"issue":"Supp 1","key":"482_CR1","first-page":"34S","volume":"48","author":"P Brugarolas","year":"2020","unstructured":"Brugarolas P, Comstock J, Dick DW, Ellmer T, Engle JW, Lapi SE, et al. Fifty Years of radiopharmaceuticals. J Nuclear Med Technol. 2020;48(Supp 1):34S-39S.","journal-title":"J Nuclear Med Technol"},{"issue":"7","key":"482_CR2","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.2967\/jnumed.121.263443","volume":"63","author":"S Bunning","year":"2022","unstructured":"Bunning S, Ignace C, Mattmuller S, Schwarz SW, Scott PJH, VanBrocklin HF, et al. Coalition of Drug Manufacturers Proceedings: PET drugs-a workshop on inspections management and regulatory considerations. J Nucl Med. 2022;63(7):1117\u201323.","journal-title":"J Nucl Med"},{"issue":"9","key":"482_CR3","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.2967\/jnumed.125.270011","volume":"66","author":"S Bunning","year":"2025","unstructured":"Bunning S, Christodoulou D, Cohen JE, Cutler CS, Dick DW, Ghosh K, et al. Proceedings: PET drugs-A 2023 workshop on product quality, regulatory submissions, facility inspections, and benefit-risk considerations. J Nucl Med. 2025;66(9):1480\u201392.","journal-title":"J Nucl Med"},{"issue":"4","key":"482_CR4","doi-asserted-by":"publisher","first-page":"e220157","DOI":"10.1148\/rycan.220157","volume":"5","author":"BJ Burkett","year":"2023","unstructured":"Burkett BJ, Bartlett DJ, McGarrah PW, Lewis AR, Johnson DR, Berbero\u011flu K, et al. A review of theranostics: perspectives on emerging approaches and clinical advancements. Radiol Imaging Cancer. 2023;5(4):e220157.","journal-title":"Radiol Imaging Cancer"},{"key":"482_CR5","doi-asserted-by":"publisher","DOI":"10.1007\/s40487-026-00432-z","author":"D Deandreis","year":"2026","unstructured":"Deandreis D, Jacene H, Therasse P, Andr\u00e9 F, Barlesi F, Haigis K, et al. Radiopharmaceutical therapy in oncology: perspectives from transatlantic experts. Oncol Ther. 2026. https:\/\/doi.org\/10.1007\/s40487-026-00432-z.","journal-title":"Oncol Ther"},{"key":"482_CR6","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s40001-023-01627-0","volume":"29","author":"S Dhoundiyal","year":"2024","unstructured":"Dhoundiyal S, Srivastava S, Kumar S, Singh G, Ashique S, Pal R, et al. Radiopharmaceuticals: navigating the frontier of precision medicine and therapeutic innovation. Eur J Med Res. 2024;29:26.","journal-title":"Eur J Med Res"},{"key":"482_CR7","doi-asserted-by":"crossref","unstructured":"Donnelly, D.J. PET Imaging in Drug Discovery and Development. In Handbook of Radiopharmaceuticals (eds P. Scott and M. Kilbourn), John Wiley and Sons, Chichester. 2020","DOI":"10.1002\/9781119500575.ch22"},{"key":"482_CR8","unstructured":"Food and Drug Administration Center for Drug Evaluation and Research (CDER), Microdose Radiopharmaceutical Diagnostic Drugs: Nonclinical Study Recommendations Guidance for Industry, August 2018. https:\/\/www.fda.gov\/media\/107641\/download. 2026. Accessed 26-May-"},{"issue":"3","key":"482_CR9","doi-asserted-by":"publisher","first-page":"117202","DOI":"10.1016\/j.bcp.2025.117202","volume":"242","author":"P Garg","year":"2025","unstructured":"Garg P, Singhal G, Horne D, Kulkarni P, Salgia R, Singhal SS. Molecular PET imaging: unlocking the secrets of cancer metabolism. Biochem Pharmacol. 2025;242(3):117202.","journal-title":"Biochem Pharmacol"},{"key":"482_CR10","doi-asserted-by":"crossref","unstructured":"Hesslewood SR, Keeling DH, and Radiopharmacy Committee of the European Association of Nuclear Medicine. Frequency of adverse reactions to radiopharmaceuticals in Europe. Eur J Nucl Med, 1997; 24: 1179-1182","DOI":"10.1007\/BF01254254"},{"key":"482_CR11","unstructured":"IMV 2024 PET Imaging Market Summary Report, 2024. IMV, Arlington"},{"key":"482_CR12","doi-asserted-by":"publisher","first-page":"1407366","DOI":"10.3389\/fphar.2024.1407366","volume":"15","author":"S Karim","year":"2024","unstructured":"Karim S, Siddiqui NA, Khan MI, Wahajuddin M, Syed S. Editorial: novel theranostic agents for precision therapeutics. Front Pharmacol. 2024;15:1407366.","journal-title":"Front Pharmacol"},{"key":"482_CR13","doi-asserted-by":"publisher","first-page":"112306","DOI":"10.1016\/j.apradiso.2025.112306","volume":"228","author":"M Karpuz","year":"2026","unstructured":"Karpuz M, Aksoyalp Z\u015e. A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) for therapeutic radiopharmaceuticals. Appl Radiat Isot. 2026;228:112306.","journal-title":"Appl Radiat Isot"},{"issue":"12","key":"482_CR14","doi-asserted-by":"publisher","first-page":"2010","DOI":"10.2967\/jnumed.117.194092","volume":"58","author":"TG Kennedy-Dixon","year":"2017","unstructured":"Kennedy-Dixon TG, Gossell-Williams M, Cooper M, Trabelsi M, Vinjamuri S. Evaluation of radiopharmaceutical adverse reaction reports to the British Nuclear Medicine Society from 2007 to 2016. J Nucl Med. 2017;58(12):2010\u20132.","journal-title":"J Nucl Med"},{"issue":"2","key":"482_CR15","doi-asserted-by":"publisher","first-page":"163","DOI":"10.4103\/ijnm.ijnm_219_20","volume":"36","author":"BR Meher","year":"2021","unstructured":"Meher BR, Agrawal K, Gnanasegaran G. Review of adverse reactions associated with the use of common diagnostic radiopharmaceuticals. Indian J Nucl Med. 2021;36(2):163\u20137.","journal-title":"Indian J Nucl Med"},{"key":"482_CR16","doi-asserted-by":"publisher","first-page":"103857","DOI":"10.1016\/j.clon.2025.103857","volume":"43","author":"MR Mititelu","year":"2025","unstructured":"Mititelu MR, Stanulovic V, Mitoi A, Bucurica S, Hodolic M, Kairemo K. Overview of adverse reactions of radiopharmaceuticals. Clin Oncol. 2025;43:103857.","journal-title":"Clin Oncol"},{"issue":"3","key":"482_CR17","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1097\/PPO.0000000000000716","volume":"30","author":"AR Pantel","year":"2024","unstructured":"Pantel AR, Bae SW, Li EJ, O\u2019Brien SR, Manning HC. PET imaging of metabolism, perfusion, and hypoxia FDG and beyond. Cancer J. 2024;30(3):159\u201369.","journal-title":"Cancer J"},{"issue":"5","key":"482_CR18","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1053\/j.semnuclmed.2019.06.006","volume":"49","author":"N Schreuder","year":"2019","unstructured":"Schreuder N, Koopman D, Jager PL, Kosterink JGW, van Puijenbroek E. Adverse events of diagnostic radiopharmaceuticals: a systematic review. Semin Nucl Med. 2019;49(5):382\u2013410.","journal-title":"Semin Nucl Med"},{"issue":"2","key":"482_CR19","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/s40264-020-01006-2","volume":"44","author":"N Schreuder","year":"2021","unstructured":"Schreuder N, Jacobs NA, Jager PL, Kosterink JGW, van Puijenbroek EP. Patient-reported adverse events of radiopharmaceuticals: a prospective study of 1002 patients. Drug Saf. 2021;44(2):211\u201322.","journal-title":"Drug Saf"},{"issue":"7","key":"482_CR20","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.2967\/jnumed.113.132472","volume":"55","author":"SW Schwarz","year":"2014","unstructured":"Schwarz SW, Dick D, VanBrocklin HF, Hoffman JM. Regulatory requirements for PET drug production. J Nucl Med. 2014;55(7):1132\u20137.","journal-title":"J Nucl Med"},{"issue":"2","key":"482_CR21","doi-asserted-by":"publisher","first-page":"327","DOI":"10.2967\/jnumed.125.271221","volume":"67","author":"PJH Scott","year":"2026","unstructured":"Scott PJH, VanBrocklin HF, Cumming RC, Dick DW, Ignace C, Bunning S, et al. FDA investigator training for PET drug manufacturing inspections. J Nucl Med. 2026;67(2):327\u20138.","journal-title":"J Nucl Med"},{"issue":"9","key":"482_CR22","doi-asserted-by":"publisher","first-page":"e0332079","DOI":"10.1371\/journal.pone.0332079","volume":"20","author":"N Shen","year":"2025","unstructured":"Shen N, Fang Q, Wu Y, Lan L, Ma F. Drug-induced vitiligo: a real-world pharmacovigilance analysis of the FAERS database. PLoS ONE. 2025;20(9):e0332079.","journal-title":"PLoS ONE"},{"issue":"12","key":"482_CR23","first-page":"2190","volume":"39","author":"EB Silberstein","year":"1998","unstructured":"Silberstein EB. Prevalence of adverse reactions to positron emitting radiopharmaceuticals in nuclear medicine. Pharmacopeia Committee of the Society of Nuclear Medicine. J Nucl Med. 1998;39(12):2190\u20132.","journal-title":"J Nucl Med"},{"issue":"1","key":"482_CR24","first-page":"13","volume":"16","author":"EB Silberstein","year":"2001","unstructured":"Silberstein EB. Positron-emitting radiopharmaceuticals: How safe are they? Cancer Biother Radiopharm. 2001;16(1):13\u20135.","journal-title":"Cancer Biother Radiopharm"},{"issue":"8","key":"482_CR25","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.2967\/jnumed.114.138057","volume":"55","author":"EB Silberstein","year":"2014","unstructured":"Silberstein EB. Prevalence of adverse events to radiopharmaceuticals from 2007 to 2011. J Nucl Med. 2014;55(8):1308\u201310.","journal-title":"J Nucl Med"},{"issue":"1","key":"482_CR26","first-page":"185","volume":"37","author":"EB Silberstein","year":"1996","unstructured":"Silberstein EB, Ryan J. Prevalence of adverse reactions in nuclear medicine. Pharmacopeia Committee of the Society of Nuclear Medicine. J Nucl Med off Public Soc Nucl Med. 1996;37(1):185\u201392.","journal-title":"J Nucl Med off Public Soc Nucl Med"},{"issue":"12","key":"482_CR27","doi-asserted-by":"publisher","first-page":"6093","DOI":"10.1007\/s10967-024-09776-0","volume":"333","author":"M Silindir-Gunay","year":"2024","unstructured":"Silindir-Gunay M, Ozolmez N. Adverse reactions to positron-emitting radiopharmaceuticals. J Radioanal Nucl Chem. 2024;333(12):6093\u2013105.","journal-title":"J Radioanal Nucl Chem"},{"issue":"1","key":"482_CR28","doi-asserted-by":"publisher","first-page":"2514155","DOI":"10.1080\/20523211.2025.2514155","volume":"18","author":"B Tong","year":"2025","unstructured":"Tong B, Wang J, Zhang Y, Liu Y, Wang J, Duan L, et al. A real-world study based on the FAERS database evaluating adverse drug reactions in three amphotericin B lipid formulations. J Pharm Policy Pract. 2025;18(1):2514155.","journal-title":"J Pharm Policy Pract"},{"key":"482_CR29","unstructured":"U.S. Food and Drug Administration. Approved drug products with therapeutic equivalence evaluations. https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/approved-drug-products-therapeutic-equivalence-evaluations-orange-book. 2026a. Accessed 26 May 2026."},{"key":"482_CR30","unstructured":"U.S. Food and Drug Administration. IND Application Reporting: Safety Reports. https:\/\/www.fda.gov\/drugs\/investigational-new-drug-ind-application\/ind-application-reporting-safety-reports. 2026b. Accessed 26 May 2026."},{"key":"482_CR31","unstructured":"U.S. Food and Drug Administration. https:\/\/www.fda.gov\/drugs\/fdas-adverse-event-reporting-system-faers\/fda-adverse-event-reporting-system-faers-public-dashboard. 2026c. Accessed 26 May 2026."},{"key":"482_CR32","doi-asserted-by":"publisher","first-page":"1693090","DOI":"10.3389\/fphar.2025.1693090","volume":"16","author":"Y Wu","year":"2025","unstructured":"Wu Y, Ke W, Li H. A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for etrasimod. Front Pharmacol. 2025;16:1693090.","journal-title":"Front Pharmacol"},{"key":"482_CR33","doi-asserted-by":"publisher","first-page":"121039","DOI":"10.1016\/j.jad.2025.121039","volume":"398","author":"M Zhang","year":"2026","unstructured":"Zhang M, Huang J, Zheng X, Zheng S, Shi J, Huang P, et al. A real-world pharmacovigilance study of modafinil events in the FDA adverse event reporting system (FAERS). J Affect Disord. 2026;398:121039.","journal-title":"J Affect Disord"}],"container-title":["EJNMMI Radiopharmacy and Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41181-026-00482-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41181-026-00482-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41181-026-00482-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T19:02:18Z","timestamp":1792522938000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41181-026-00482-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,23]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["482"],"URL":"https:\/\/doi.org\/10.1186\/s41181-026-00482-8","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-9826575\/v1","asserted-by":"object"}]},"ISSN":["2365-421X"],"issn-type":[{"value":"2365-421X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,23]]},"assertion":[{"value":"27 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This article does not contain any original studies with human or animal subjects performed by any of the authors.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"SSZ is an employee of Siemens PETNET Solutions. In addition to their primary employment, SSZ, HVB, and PJHS hold volunteer leadership positions at the Coalition of PET Drug Manufacturers, a 501(c)(6) trade association operating as a not-for-profit organization dedicated to the advancement of scientific and regulatory principles associated with the manufacturing and distribution of safe and effective drugs for diagnostic PET imaging. MD is a member and involved with various committees at the Coalition. Due to his role as an Associate Editor, PJHS was not involved in the peer-review of this article and has no access to information regarding its peer-review.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"77"}}